

Roche's Announcement Regarding giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast Cancer at ESMO)

TOKYO, October 20, 2025 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on October 18, including the latest data of giredestrant for estrogen receptor (ER)- positive breast cancer, presented at the European Society for Medical Oncology Congress (ESMO) 2025.

Please refer to the link below for details of the press release:

Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

<https://www.roche.com/media/releases/med-cor-2025-10-18>

###